This clinical trial is focused on studying a condition called ulcerative colitis, which is a chronic disease that causes inflammation and sores in the digestive tract, specifically affecting the innermost lining of the large intestine and rectum. The study is comparing two treatments: an investigational treatment known as PB016 and a licensed treatment called Entyvio. Both treatments involve the use of a substance called vedolizumab, which is a type of protein designed to help reduce inflammation in the gut.

The purpose of the study is to evaluate how well PB016 works and how safe it is compared to Entyvio in people with moderately to severely active ulcerative colitis. Participants in the study will receive one of these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will last for a period of up to 46 weeks, during which participants will be monitored to see how their condition responds to the treatment. The study will also look at the safety of the treatments and any potential side effects.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. This includes monitoring changes in symptoms and any improvements in their condition. The study aims to provide valuable information on the potential benefits and risks of using PB016 compared to Entyvio for treating ulcerative colitis, helping to improve future treatment options for this condition.